Glorimet VG 1 Tablet is a combination oral hypoglycemic agent containing Glimepiride (1mg), Metformin (500mg), and Voglibose (0.2mg), designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, leading to enhanced glucose uptake and utilization. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, resulting in a reduction of postprandial hyperglycemia. The synergistic action of these three agents provides comprehensive glycemic control by targeting multiple pathophysiological defects in type 2 diabetes. Glorimet VG 1 is indicated for patients inadequately controlled on diet, exercise, and monotherapy with either sulfonylurea or metformin. It should be used under strict medical supervision with regular monitoring of blood glucose and renal function. Common side effects may include gastrointestinal disturbances, hypoglycemia, and rare allergic reactions. Dose adjustment may be necessary in renal impairment. This combination therapy aims to improve glycemic control, reduce the risk of diabetes-related complications, and enhance patient compliance by minimizing pill burden.